ASX BRIEFS
Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.
ASX BRIEFS
OPTISCAN IMAGING (OIL) - Pioneering Precision Surgery: CEO Camile Farah on the Game-Changing InVue Device and Transformative Partnership with the Mayo Clinic
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Unlock the future of precision surgery with Camile Farah, the trailblazing CEO of Optiscan Imaging. In our latest ASX Briefs episode, Camile uncovers the revolutionary InVue device, a game-changer in cancer treatment. Imagine surgeons being able to see individual cancer cells in real-time—this isn't science fiction, it's happening now, and it's dramatically improving surgical outcomes. Camile shares how this cutting-edge technology reduces the need for second-stage surgeries, alleviates patient anxiety, and transforms the entire surgical workflow.
We also delve into Optiscan's strategic moves in the surgical market and their exciting partnership with the Mayo Clinic to advance robotic surgery technology. Camile's insights reveal how high-resolution, sub-micron level imaging is setting new standards in medical technology, empowering surgeons to make more informed decisions on the spot. Whether you're a healthcare professional, a tech enthusiast, or someone intrigued by medical innovations, this episode is packed with invaluable information on how Optiscan is leading the charge in precision surgery.
Welcome to another episode of ASX Briefs , where we dive into the innovations shaping the future of medical technology . And joining me today is Camile Farah , the CEO of Optiscan Imaging , which is renowned for its pioneering work in endomicroscopy , and they're making significant strides with their latest In-Vue imaging device tailored for precision surgery . We'll explore how their technology is enhancing surgical accuracy and transforming cancer diagnosis and treatment . Camile , thanks for joining me today and welcome to the podcast .
Camile FarahThanks very much for having me .
Andrew MusgraveOkay , let's start by talking about the In-Vue device . So can you give us an idea or an overview of how the device works and what its capabilities are in the surgical setting ?
Camile FarahYeah , thank you . So this device is basically created specifically to assist surgeons while they're doing their surgery specifically for cancer treatment , where typically surgeons would remove a tumor and then either inspect that area visually or then palpate the area with their finger to determine whether the tumor has been removed completely . We're providing them with higher resolution , very precise technology that they can use to essentially see in real time individual cancer cells while they're doing surgery and obviously , the idea behind that is that they'll get the tumor out precisely and that will have better outcomes for the patient .
Andrew MusgraveOkay , and you've also recently expanded its technological applications to the surgical market . So what prompted this strategic move and how do you see it impacting the company's growth ?
Camile FarahYeah , so we've been transforming the business over the last couple of years with a focus on the surgical market . We believe , because of the high precision that our technology offers and the high accuracy of the imaging , we can image down to sub-micron levels in real time , which is a very difficult feat to undertake . We believe that is really useful for the surgical marketplace , given the lack of any precision technology that surgeons use currently . So it's been a very strategic focus for us and we're basically trying to work towards our own strengths . And we've also had a lot of positive feedback by demonstrating our technology to various surgical disciplines , and so that feedback has also assisted us to make that decision along the way .
Andrew MusgraveOkay , and if we look at clinical applications in a little bit more detail , so the In-Vue device seems set to revolutionize how surgeries are performed , particularly with cancer treatment . So can you discuss how the technology actually enhances that decision-making process ?
Camile FarahYeah . So the imaging resolution that we have with our technology is a thousand times that what you would get , for example , with a standard medical CT or an MR machine , given that surgeons typically would use low-level magnification or , as I said earlier , their finger to palpate the presence or absence of a tumor . Obviously what we're trying to do is to give them that ability to see individual cancer cells in real time . Now that opens up a whole myriad of differences for them in their workflow . Typically , the patient would be sent home after the surgeon believes they've got the whole tumor out . The sample would be sent to the pathologist and then a couple of weeks later the pathologist would send a report to the surgeon and tell them whether indeed they had the whole tumor out or not . And then of course , the surgeon shares that with the patient .
Camile FarahBut unfortunately in many instances the tumor is not removed in its completeness . So , for example , if you look at breast cancer surgery , a third of all patients come back for a second stage surgery a couple of weeks after their first surgical procedure . They have to go through that whole anxiety again or the trauma of having a second stage surgery , and of course that ties up a whole myriad of resources in the health sector . So we believe that our technology will allow surgeons to make really informed decisions on the spot , with information that's never been available to them before , in real time , and of course then they can change how they do their surgery . They can remove a little bit of extra tumor if they believe that it's still there , and obviously eliminate the need to bring patients back for second stage surgeries and minimize the trauma to them . Of course , the workload onto the surgeon themselves , but also the hospital system .
Andrew MusgraveOkay , and you've also announced a significant partnership with the Mayo Clinic to develop a system for use in robotic surgery . So how will this collaboration influence the company's product development and market reach ?
Camile FarahYeah .
Camile FarahSo that's another very strategic decision that we've made to move into robotics again with the high precision and accuracy that our technology offers and that high precision and accuracy required with robotic surgery .
Camile FarahWe believe there's significant synergies there between the two platforms . So we've pursued robotic surgery again under that larger umbrella of surgical intervention and precise precision surgery technology for growth of the business , and we wanted to partner with a clinical entity that basically had made significant strides in the context of high quality patient care but also was at the leading edge of robotic surgery , and the Mayo definitely ticks both of those boxes . So they're always wanting to expand surgical applications of robotics and they're involved in a whole myriad of robotic trials and a lot of their surgery has already moved to robotic surgery . So again they were looking for a tool that could allow their surgeons to see in real time , to make decisions in real time , but that could easily interface with the robotic platform . So from that earlier discussions about 18 months ago came this partnership where we'll develop this imaging platform that's compatible with robotic surgery devices and hopefully over the next couple of years we'll be able to bring a prototype to market and then obviously from there take it through the regulatory pathway .
Andrew MusgraveOkay , and then just touching on the regulatory landscape , what are some of the challenges you face with such innovative medical devices and how is the company navigating these hurdles ?
Camile FarahYeah , with new technology , getting the FDA to understand what the technology does is always the first step , because obviously having a great working relationship with a regulator in navigating that pathway is very important . So we're extremely focused on the US market at present . We work closely with the FDA . We've got consultants who help us navigate that maze of guidelines and guidances that the FDA put out , and we're in constant contact with them to make sure that we select the most appropriate pathway to bring these sorts of products to market . Typically , the stage that we're at now with the development , we're at the clinical trial stage . So all of the product development has been vetted and signed off on . We're about to embark on a clinical study for breast cancer imaging in the US in 2025 , and we're working with the FDA currently to get our paperwork in order to make sure that we can start that next year . We'll accrue patients over the next couple of years with the idea of submitting our submission to the FDA late 26 , early 27 for clearance .
Andrew MusgraveAnd at more of a macro level , could you share how Optiscan's technologies , particularly the In-Vue , are expected to improve patient outcomes and potentially reduce healthcare costs ?
Camile FarahYeah , so I alluded to that example earlier . With breast cancer surgery , about a third of patients come back to have a second stage procedure a couple of weeks after their first cancer has been removed . We believe that's inappropriate and in this day and age with advanced technology , that really shouldn't be happening . The surgeons don't want that to happen , obviously , the patients don't want that to happen and the hospital system doesn't want that to happen . So there's a significant amount of positive outcomes for patients when those surgeries can be done in one procedure the tumor removed completely and the patient given that peace of mind to make sure that they've got all of their tumor out .
Camile FarahYou can imagine then if a third of patients are coming back to have their surgery done again in the US . For example , looking at breast cancer numbers , there are 300,000 new cases of breast cancer in the US every year and imagine 100,000 of those are coming back and having another procedure . That's 100,000 operating room hours that basically can be had for another procedure . Additionally , if you use our technology in the operating theater , our calculations show that you can basically complete the procedure in a shorter period of time . So our modeling shows that our technology can cut the time of the procedure down by 25% . So again , for every surgical intervention that the patient goes through , typically it might be two or three hours to remove that tumor .
Camile FarahIf we can shave off 25% of that , again that opens up the operating rooms and the hospital beds to other patients requiring other sorts of procedures and of course there are significant then cost savings for the hospital system and the wider healthcare system . There are other benefits , of course . Immediate informed decisions really allows you to give patients that understanding of what's occurring in real time with digital pathology . So we've got some modelling that also shows that the digital workflow can significantly cut down on the time spent of the sample in the path lab and how much time the pathologist is actually spending to come up with an answer for the surgeon . So there's cost savings in the operating room and there's cost savings in the pathology lab and between that there's obviously significant cost savings for the healthcare system .
Andrew MusgraveOkay , and just to wrap things up , what are some of the key milestones you're looking to achieve in the next 12 to 18 months ?
Camile FarahYeah , so obviously , commencing recruitment for our breast cancer study in the US is a significant milestone and catalyst for us over this new financial year . We're in constant contact again , as I alluded to earlier with the FDA , so the FDA green lighting our approach as to how we're going to bring this imaging platform to the market , and we're also discussing and exploring other opportunities for our devices to be integrated into different hospital workflows . So whether that's in pathology or that may be in a different part of the healthcare system , so there'll be some milestones that we're looking to hit in that regard . Also , and in a broader sense , of course , generating revenue from some of our preclinical life sciences devices is very important to make sure that we can get through the clinical trial phase and get these devices to market . So there'll be a good flow of positive news over the next six to 12 months , so we look forward to sharing that with everyone .
Andrew MusgraveAll right , Camile . Well , thanks for your time today . It's been great to get an update on where the company is at , and we look forward to further updates in the upcoming months .
Camile FarahThank you very much , appreciate it .
Andrew MusgraveThat concludes this episode of ASX Briefs . Don't forget to subscribe and we look forward to catching you on our next episode .